Swiss guidelines for counseling and testing for genetic predisposition to breast and ovarian cancer


¹ Division of Oncology and Division of Genetic Medicine, University Hospitals of Geneva, CH-1205 Geneva
² Tumor- und Brustzentrum ZeTuP, CH-9006 St.-Gallen
³ Division of Gynecologic Oncology, University Hospital Basel, CH-4055 Basel
⁴ Sonnenhof Klinik Engeried, CH-3012 Bern
⁵ Division of Medical Genetics, University Hospital Basel, CH-4031 Basel
⁶ Division of Oncology, Hôpital du Jura-Delémont, CH-2800 Delémont
⁷ Tumorzentrum ZeTuP, Rapperswil-Jona, CH-8640 Rapperswil
⁸ Istituto Oncologico della Svizzera Italiana, Ospedale Regionale Bellinzona e Valli, CH-6500 Bellinzona
⁹ Division of Oncology, Hôpital de Morges, CH-1110 Morges
¹⁰ Division of Medical Oncology, UCI University Cancer Center Inselspital, CH-3010 Bern
¹¹ Division of Medical Genetics, CHUV-Lausanne University Hospital, CH-1011 Lausanne

*these authors contributed equally to this publication

These guidelines have been approved by the SAKK Breast Cancer Project Group and the Gynecological Cancers Working Group. This document reflects clinical and scientific advances as of the date of publication and is subject to change.

Corresponding author: PD Dr. med. Pierre O. Chappuis
Unit of oncogenetics and cancer prevention
Division of Oncology
University Hospitals of Geneva (HUG)
Bd. de la Cluse 30
CH-1205 Geneva
Phone: + 41 (0)22 372 98 53
Fax: + 41 (0)22 372 33 63
Email: pierre.chappuis@hcuge.ch
Introduction

BRCA1 and BRCA2 are the main genes involved in the hereditary breast and ovarian cancer syndrome with an autosomal dominant mode of inheritance. The frequency of germ-line BRCA1/BRCA2 pathogenic variants is about 1:400 to 1:800 among healthy women from the Western non-Jewish white population. Carrying a germ-line mutation in BRCA1 or BRCA2 is associated with 40% to 75% cumulative risk of developing breast cancer and 15% to 60% cumulative risk for ovarian cancer by age 70 years [1]. About 3-5% of all breast cancer and 10-15% of unselected invasive ovarian cancer cases are BRCA-related [2]. Other rare high- to moderate-risk inherited syndromes can associate breast or ovarian cancer [3, 4].

The rapid translation of next generation or massively parallel sequencing technology in diagnostic laboratory has opened impressive perspectives by allowing to test for multiple genes in a single assay (gene panel or exome) with substantial reductions both in costs and turn-around time. Some important issues have also been raised by this technological revolution, e.g. clinical validity or clinical utility of several genetic results, or identification of multiple variants of uncertain clinical significance [5, 6].

In Switzerland, testing for genetic predisposition to hereditary breast/ovarian cancer, particularly BRCA1/BRCA2, is available in a clinical setting. Cancer risk assessment and genetic counseling are mandatory before and after genetic testing (i.e. pre- and post-test counseling). This genetic analysis is covered by health insurances only after formal genetic counseling and informed consent according to the KVL/OPAS/OPre art. 12d, let. f [7]. Twenty-five centres throughout Switzerland are currently doing risk-assessment and counseling individuals with an increased risk for hereditary breast/ovarian cancer syndromes [cf. Annex]. Routine BRCA1 or BRCA2 testing is not recommended [4, 8-10]. Only individuals with a personal history or whose maternal or paternal family history is suggestive of an increased risk of pathogenic variants in high-risk cancer predisposition genes should be referred for counseling and considered for genetic testing, if they agree with this procedure. Targeted medical interventions such as intensive screening, prophylactic surgery, or chemoprevention can be recommended according to the individual risk situation, and particularly to unaffected family members identified as carriers of pathogenic genetic variants [2, 4, 10, 11].

Swiss guidelines for genetic counseling and testing for breast and ovarian cancer predisposition

The present paper summarises the Swiss guidelines for genetic counseling and ultimately testing individuals with an increased probability for carrying mutations in high-risk breast/ovarian cancer predisposition genes, particularly BRCA1/BRCA2. Risk-assessment is mainly based on some particular personal and/or family history patterns on both side of the family, including:

- early-age of onset of breast cancer;
- number of breast cancer cases across generations;
- bilateral breast cancer;
- ovarian cancer: of note, peritoneal and fallopian tube cancers should be considered as part of the spectrum of the hereditary breast/ovarian cancer syndrome;
- ethnic origin: currently limited to Ashkenazi Jews in our population.
Adapted from recently published guidelines [3, 4, 8, 10, 12], it is reasonable to refer individuals with the following personal and/or family history for genetic counseling and considering testing for high-risk predisposition genes, particularly BRCA1/BRCA2 (Table 1).

Table 1. Swiss guidelines for referral individuals for risk assessment, genetic counseling and testing for breast/ovarian cancer predisposition syndrome.

| I. | Individuals with a close relative\(^1\) with a known pathogenic variant in BRCA1 or BRCA2, or in another gene conferring high risk for breast and ovarian cancer. |
| II. | WOMEN with a personal history of BREAST CANCER and one of the following: |
| | • Age at diagnosis < 40 years; |
| | • Triple negative (estrogen receptor, progesterone receptor and HER2 negative) breast cancer ≤ 60 years; |
| | • Age at diagnosis ≤ 50 years, with ≥ 2 close relatives\(^1\) with breast cancer at any age or with only 1 close relative\(^1\) with breast cancer ≤ 50 years; |
| | • Bilateral breast cancer, if the first cancer was diagnosed ≤ 50 years; |
| | • Bilateral breast cancer at any age, with ≥ 1 close relative\(^1\) with breast cancer [if only one relative affected, then age at diagnosis ≤ 50 years]; |
| | • Diagnosed at any age, with ≥ 1 close relative\(^1\) with ovarian\(^2\) cancer at any age; |
| | • Diagnosed at any age, with ≥ 2 close relatives\(^1\) with breast cancer [particularly if ≥ 1 breast cancer diagnosed ≤ 50 years or if bilateral breast cancer]; |
| | • A close male relative\(^1\) with breast cancer (any age); |
| | • A personal history of ovarian\(^2\) cancer; |

| III. | Women with a personal history of OVARIAN\(^2\) CANCER and one of the following: |
| | • Non-mucinous epithelial subtypes, particularly high grade serous histology, at any age; |
| | • A personal history of breast cancer; |
| | • One or more close relatives\(^1\) with ovarian\(^2\) cancer (any age); |
| | • One or more close female or male relatives\(^1\) with breast cancer, particularly if breast cancer diagnosed ≤ 50 years; |

| IV. | MEN with a personal history of BREAST CANCER: |
| | • Particularly, if one or more close male relatives\(^1\) with breast cancer; |
| | • Particularly, if one or more close female relatives\(^1\) with breast or ovarian\(^2\) cancer; |

| V. | Ashkenazi Jewish heritage: |
| | • Search for the 3 founder BRCA1 and BRCA2 pathogenic variants\(^3\) regardless of personal or family history; |

| VI. | Family history only (i.e. unaffected individuals): |
| | • One or more close relatives\(^1\) with breast or ovarian\(^2\) cancer fulfilling one of the above criteria (points II-IV). |

\(^1\) Close relative is defined as a first- or a second-degree relative on the same side of the family.
- first-degree relatives: mother/father, sister/brother, daughter/son;
- second-degree relatives: grandparents, aunt/uncle, niece/nephew, grandchildren.

\(^2\) Ovarian cancer also includes primary peritoneal cancer and fallopian tube cancer.

\(^3\) BRCA1: c.68_69delAG, c.5266dupC; BRCA2: c.5946delT.
Comments

1) Meeting one or more of these criteria warrants further personalized genetic risk assessment and genetic counseling which will cover explanation of inheritance pattern, available testing options, discussion of disease management, treatment, surveillance and prevention options.

2) Consider referral of cases with a weaker history of breast cancer if there is a family history of pancreatic cancer or prostate cancer, particularly at an early age at diagnosis (≤ 60 years), or sarcoma < 45 years, or glioma, or childhood adrenal cortical carcinoma, or complicated patterns of multiple cancers at a young age.

3) Particular clinical situations not included in one of the above criteria should be discussed individually, e.g. ductal carcinoma in situ (DCIS) at an early age of onset (< 40 years), small or uninformative families or adoption.

4) Borderline ovarian tumour is not considered as part of the spectrum of the hereditary breast/ovarian cancer syndrome.

5) Among the Ashkenazi Jewish population, the 3 BRCA1 and BRCA2 founder pathogenic variants (BRCA1: c.68_69delAG, c.5266dupC; BRCA2: c.5946delT) account for 98-99% of mutations identified and are carried by about 2.6% (1/40) of this population.

6) When an appropriate affected family member is unavailable, testing of a family relative without a cancer diagnosis should be considered.

7) Genetic testing for adult onset diseases, such as BRCA1/BRCA2-related disorders, is not recommended in children <18 years.

8) Genetic testing on formalin-fixed and paraffin-embedded tumoral tissue is yet feasible to identify mutations predictive of response to treatment, e.g. identification of somatic or potentially germ-line BRCA1 or BRCA2 pathogenic variants and decision to introduce platinum-based drugs or poly(ADP-ribose) polymerase inhibitors. Currently, this molecular approach does not replace the search for germ-line pathogenic variants based on a blood sample in the context of a suspicion of genetic predisposition to hereditary breast/ovarian cancer.

Conclusion

Cancer genetic predisposition is a complex clinical and socio-psychological condition which requires harmonization in medical practice and close interdisciplinary collaboration. An adequate identification of individuals who can potentially benefit from genetic counseling and testing is the essential prerequisite for a positive risk/benefit ratio [9]. Health care professionals should therefore be aware of the personal and/or family history patterns that are associated with an increased risk for germ-line pathogenic variants to allow for the most effective management of hereditary breast and ovarian cancer families and the most efficient utilization of health care resources.
References


Annex.

Address and contact information of the Swiss centres that offer genetic counseling and evaluation for cancer predisposition gene testing according to the Swiss regulation of the Krankenpflege Leistungsverordnung (KVL)/Ordonnance sur les prestations de l’assurance des soins (OPAS)/Ordinanza sulle prestazioni (OPre) [7]. Regular update on [http://sakk.ch/en/sakk-provides-for-patients/genetic-counseling/](http://sakk.ch/en/sakk-provides-for-patients/genetic-counseling/)

**Aarau**

Dr. Benno ROTHlisberger  
Institut für Labormedizin  
Zentrum für Onkologie/Hämatologie  
Kantonsspital Aarau  
Tellstrasse 5  
5001 Aarau  
Tel: 062 838 53 00  
Fax: 062 838 53 99

**Baden**

PD Dr. Cornelia LEO  
Brustzentrum  
Frauenklinik  
Kantonsspital Baden  
5404 Baden  
Tel: 056 486 36 36  
Fax: 056 486 35 09

**Basel**

PD Dr. Nicole BÜRKI  
Gynäkologische Onkologie  
Universitätsspital Basel  
Spitalstrasse 21  
4055 Basel  
Tel: 061 265 93 93

Aeschenpraxis  
Aeschenvorstadt 21  
4051 Basel  
Tel: 061 271 75 75  
Fax: 061 271 75 85

Prof. Dr. Karl HEINIMANN  
Prof. Dr. Hansjakob MÜLLER  
Medizinische Genetik  
Universitätsspital Basel  
Schönbeinstrasse 40  
4031 Basel  
Tel: 061 265 36 20  
Fax: 061 265 36 21

PD Dr. Dieter KÖBERLE  
Fachbereich Onkologie  
St. Claraspital  
Kleinriehenstrasse 30  
4058 Basel  
Tel: 061 685 85 85  
Fax: 061 685 83 47

Prof. Dr. Hans-Rudolf STOLL, PhD  
Familiäre Tumorerkrankungen  
Kantonsspital Basel  
4051 Basel  
Tel: 061 265 50 03  
Fax: 061 265 53 16

Prof. Dr. Walter WEBER-STADELMANN  
Onkologische Praxis  
Heuberg 16  
4031 Basel  
Tel: 061 261 02 25  
Fax: 061 261 02 25
**Bern**

Dr. Katharina BUSER  
PD Dr. Gabriella PICHERT  
Praxis Oncocare  
Sonnenhof Klinik Engeried  
Riedweg 15  
3012 Bern

Dr. Manuela RABAGLIO  
Dr. Benno RÖTLISBERGER  
Dr. Laura KNABBEN  
Dr. Henrik HORVATH  
UCi University Cancer Center Inselspital  
Freiburgstrasse 4  
CH-3010 Bern

**Genève**

PD Dr. Pierre O. CHAPPUIS  
Dr. Valeria VIASSOLO  
Unité d'oncogénétique et de prévention des cancers, Service d'Oncologie  
Boulevard de la Cluse 30  
1205 Genève

**Graubünden**

Kantonsspital Graubünden  
Onkologie/Hämatologie  
Loestrasse 170  
7000 Chur

**Jura**

Dr. Christian MONNERAT  
Service d'oncologie  
Hôpital du Jura-Delémont  
Faubourg des Capucins 30  
2800 Delémont

**Rapperswil**

Dr. Rudolf MORANT  
Tumorzentrum ZeTuP Rapperswil-Jona  
Alte Jonastrasse 24  
8640 Rapperswil

**Sargans**

Dr. Stefan GREUTER  
Onkologie am Bahnhof  
Bahnhofpark 2B  
7320 Sargans

**St.Gallen**

Prof. Dr. Thomas CERNY  
Fachbereich Onkologie/Hämatologie  
Kantonsspital St.Gallen  
9007 St.Gallen

Dr. Barbara BOLLIGER  
Tel: 071 243 00 43
<table>
<thead>
<tr>
<th>Location</th>
<th>Tel.</th>
<th>Fax.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Onkozentrum Hirslanden</td>
<td></td>
<td>044 387 22 75</td>
</tr>
<tr>
<td>Witellikerstrasse 40</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8032 Zürich</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Privatklinik Bethanien</td>
<td>044 262 17 75</td>
<td>044 262 50 18</td>
</tr>
<tr>
<td>Toblerstrasse 51</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8044 Zürich</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Susanna STOLL</td>
<td>044 255 21 54</td>
<td>044 255 45 48</td>
</tr>
<tr>
<td>Klinik für Onkologie</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Universitätsspital Zürich</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rämistrasse 100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8091 Zürich</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Acknowledgments

We thank all the members of the SAKK Section Network for cancer predisposition testing and counseling and other colleagues for their fruitful comments.
Conflict of interest

None of the authors have any conflict of interest to declare.